Email Us: info@lupinepublishers.com
Call Us: +1 (914) 407-6109
57 West 57th Street, 3rd floor, New York - NY 10019, USA
Lupine Publishers Group
Lupine Publishers
ISSN: 2638-5910
Review Article(ISSN: 2638-5910) 
Bromocriptine - A Novel Therapy in Type-2 Diabetes
Volume 2 - Issue 2Poondy Gopalratnam Raman*
-
Author Information
Open or Close
Poondy Gopalratnam Raman, MGM Medical College, India
Received:June 27, 2019; Published:July 09, 2019
DOI: 10.32474/ADO.2019.02.000134
Full Text
PDFAbstract
Bromocriptine is used in treatment of diabetes mellitus. It acts by increasing dopaminergic activity in hypothalamus and lowers HbA1c by 0.6 to 0.9%. It is not to be used in type 1 diabetes and DKA.
Keywords: Bromocriptine; Hypothalamus; Contra indicators; Infarction; Combination therapy; Quick release bromocriptine
-
Mark E Smith
Bio chemistry
University of Texas Medical Branch, USA -
Lawrence A Presley
Department of Criminal Justice
Liberty University, USA -
Thomas W Miller
Department of Psychiatry
University of Kentucky, USA -
Gjumrakch Aliev
Department of Medicine
Gally International Biomedical Research & Consulting LLC, USA -
Christopher Bryant
Department of Urbanisation and Agricultural
Montreal university, USA -
Robert William Frare
Oral & Maxillofacial Pathology
New York University, USA -
Rudolph Modesto Navari
Gastroenterology and Hepatology
University of Alabama, UK -
Andrew Hague
Department of Medicine
Universities of Bradford, UK -
George Gregory Buttigieg
Maltese College of Obstetrics and Gynaecology, Europe -
Chen-Hsiung Yeh
Oncology
Circulogene Theranostics, England -
.png)
Emilio Bucio-Carrillo
Radiation Chemistry
National University of Mexico, USA -
.jpg)
Casey J Grenier
Analytical Chemistry
Wentworth Institute of Technology, USA -
Hany Atalah
Minimally Invasive Surgery
Mercer University school of Medicine, USA -
Abu-Hussein Muhamad
Pediatric Dentistry
University of Athens , Greece
